Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: a randomized trial
Annals of internal medicine, 2011•acpjournals.org
Background: Limited data compare once-daily options for initial therapy for HIV-1. Objective:
To compare time to virologic failure; first grade-3 or-4 sign, symptom, or laboratory
abnormality (safety); and change or discontinuation of regimen (tolerability) for atazanavir
plus ritonavir with efavirenz-containing initial therapy for HIV-1. Design: A randomized
equivalence trial accrued from September 2005 to November 2007, with median follow-up of
138 weeks. Regimens were assigned by using a central computer, stratified by screening …
To compare time to virologic failure; first grade-3 or-4 sign, symptom, or laboratory
abnormality (safety); and change or discontinuation of regimen (tolerability) for atazanavir
plus ritonavir with efavirenz-containing initial therapy for HIV-1. Design: A randomized
equivalence trial accrued from September 2005 to November 2007, with median follow-up of
138 weeks. Regimens were assigned by using a central computer, stratified by screening …
Background
Limited data compare once-daily options for initial therapy for HIV-1.
Objective
To compare time to virologic failure; first grade-3 or -4 sign, symptom, or laboratory abnormality (safety); and change or discontinuation of regimen (tolerability) for atazanavir plus ritonavir with efavirenz-containing initial therapy for HIV-1.
Design
A randomized equivalence trial accrued from September 2005 to November 2007, with median follow-up of 138 weeks. Regimens were assigned by using a central computer, stratified by screening HIV-1 RNA level less than 100 000 copies/mL or 100 000 copies/mL or greater; blinding was known only to the site pharmacist. (ClinicalTrials.gov registration number: NCT00118898)
Setting
59 AIDS Clinical Trials Group sites in the United States and Puerto Rico.
Patients
Antiretroviral-naive patients.
Intervention
Open-label atazanavir plus ritonavir or efavirenz, each given with with placebo-controlled abacavir–lamivudine or tenofovir disoproxil fumarate (DF)–emtricitabine.
Measurements
Primary outcomes were time to virologic failure, safety, and tolerability events. Secondary end points included proportion of patients with HIV-1 RNA level less than 50 copies/mL, emergence of drug resistance, changes in CD4 cell counts, calculated creatinine clearance, and lipid levels.
Results
463 eligible patients were randomly assigned to receive atazanavir plus ritonavir and 465 were assigned to receive efavirenz, both with abacavir–lamivudine; 322 (70%) and 324 (70%), respectively, completed follow-up. The respective numbers of participants in each group who received tenofovir DF–emtricitabine were 465 and 464; 342 (74%) and 343 (74%) completed follow-up. Primary efficacy was similar in the group that received atazanavir plus ritonavir and and the group that received efavirenz and did not differ according to whether abacavir–lamivudine or tenofovir DF–emtricitabine was also given. Hazard ratios for time to virologic failure were 1.13 (95% CI, 0.82 to 1.56) and 1.01 (CI, 0.70 to 1.46), respectively, although CIs did not meet prespecified criteria for equivalence. The time to safety (P = 0.048) and tolerability (P < 0.001) events was longer in persons given atazanavir plus ritonavir than in those given efavirenz with abacavir–lamivudine but not with tenofovir DF–emtricitabine.
Limitations
Neither HLA-B*5701 nor resistance testing was the standard of care when A5202 enrolled patients. The third drugs, atazanavir plus ritonavir and efavirenz, were open-label; the nucleoside reverse transcriptase inhibitors were prematurely unblinded in the high viral load stratum; and 32% of patients modified or discontinued treatment with their third drug.
Conclusion
Atazanavir plus ritonavir and efavirenz have similar antiviral activity when used with abacavir–lamivudine or tenofovir DF–emtricitabine.
Primary Funding Source
National Institutes of Health.
acpjournals.org